AdvanCell raises $218.3 million in Rule 506(b) equity offering
AdvanCell, a Delaware biotechnology corporation, has sold $218,333,294 of a $315,000,000 equity offering under Regulation D Rule 506(b), as of June 30, 2026. The offering has attracted 41 investors to date and has $96,666,706 remaining available. No sales or finders' compensation was paid.
Key facts
- $218,333,294 sold of $315,000,000 target offering
- $96,666,706 remaining
- 41 investors to date
- Date of first sale: June 30, 2026
- Rule 506(b) exemption claimed
- Equity securities
Why it matters
AdvanCell is capitalizing its operations through a private placement that has achieved 69% of its target raise, indicating investor demand for the biotechnology company's equity in advance of further development or clinical milestones.
Share
Derived from D filed 2026-07-16. Not investment advice. View the source filing on SEC.gov →